2024-02-24 09:09:44 ET
Summary
- Bausch Health is burdened by a heavy debt load of over $20 billion, impacting its equity valuation.
- The resolution to the leverage issues lies in divesting Bausch + Lomb Corp shares, which could bring in much-needed cash to reduce debt.
- The divestiture could result in an upside potential of around 40% for Bausch Health.
Bausch Health (BHC) is a high-quality pharmaceutical company that has shown great resiliency and ability to innovate. However, it is also loaded with an expensive and heavy debt load of more than $20 billion that is weighing on the equity valuation....
Read the full article on Seeking Alpha
For further details see:
Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation